Journal of Cardiac Failure
Volume 14, Issue 8 , Pages 648-650 , October 2008

Vasopressin Antagonists for the Treatment of Acute Decompensated Heart Failure: When, for Whom, for How Long, and on What Standard Therapy?

  • Gerasimos Filippatos, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Gerasimos Filippatos, MD, Heart Failure Unit, Department of Cardiology, Athens University Hospital Attikon, Rimini 1, 12 461, Athens, Greece. Tel/Fax: +30-210-5832195.
    • ,
  • John T. Parissis, MD

References 

  1. Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. Heart Fail Rev. 2007;12:91–95
  2. Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev. 2007;12:87–90
  3. Gheorghiade M, Zannad F, Sopko G. et al, for the International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958–3968
  4. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med. 2006;119(12 Suppl 1):S3–S10
  5. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371:1624–1632
  6. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785–1791
  7. Lee CR, Watkins ML, Patterson JH, Gattis W, O'Connor CM, Gheorghiade M, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146:9–18
  8. Tahara A, Tsukada J, Tomura Y, Suzuki T, Yatsu T, Shibasaki M. Vasopressin stimulates the production of extracellular matrix by cultured rat mesangial cells. Clin Exp Pharmacol Physiol. 2008;35:586–593
  9. Goldsmith SR. Vasopressin: a therapeutic target in congestive heart failure?. J Card Fail. 1999;5:347–356
  10. Clair MJ, King MK, Goldberg AT, et al. Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. J Pharmacol Exp Ther. 2000;293:852–860
  11. De Luca L, Mebazaa A, Filippatos G, Parissis JT, Böhm M, Voors AA, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail. 2008;10:201–213
  12. Abraham W, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47:1615–1621
  13. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF, Elkayam U, Barbagelata A, et al. for the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–1971
  14. Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343
  15. Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319–1331
  16. Gheorghiade M, Niazi I, Ouyang J. et al, for the tolvaptan Investigators. Vasopressin V2-receptor blockade with Tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690–2696
  17. Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral Tolvaptan on left ventricular dilation and function in patient with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151–2159
  18. Wada K, Fujimori A, Matsukawa U, Arai Y, Sudoh K, Yatsu T, et al. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol. 2005;507:145–151
  19. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417–2423
  20. Goldsmith S, Elkayam U, Haught H, Barve A, He W. Efficacy and safety of V1A/V2-recepto Antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail. 2008;14:641–647
  21. Bolignano D, Coppolino G, Criseo M, Campo S, Romeo A, Buemi M. Aquaretic agents: what's beyond the treatment of hyponatremia?. Curr Pharm Des. 2007;13:865–871
  22. Filippatos G, Rossi J, Lloyds-Jones DM, et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail. 2007;13:360–364
  23. Rossi J, Bayram M, Udelson JE, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care. 2007;9:82–86

PII: S1071-9164(08)00952-4

doi: 10.1016/j.cardfail.2008.08.003

Journal of Cardiac Failure
Volume 14, Issue 8 , Pages 648-650 , October 2008

Article Tools